ClinicalTrials.gg
TerminatedNCT06585150Updated Jun 30, 2026Results posted

Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection

A Phase 2 interventional study of Obeldesivir and Obeldesivir Placebo in RSV Infection, sponsored by Gilead Sciences. Terminated at 121 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was terminated by Sponsor; the decision was not due to any safety findings.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 145 studies in Respiratory Syncytial Virus Infections with a site in United States — 10 open to participants now, 14 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · United States.

Enrollment
51st of 122
150 · median 88
Started
2024
with 12 others
Phase 2
28 of 145
2 open now
Registered
133rd of 145
by date
Lead sponsor
6 of 145
Gilead Sciences

Among the 145 studies in Respiratory Syncytial Virus Infections with a site in United States, this one is the 51st largest by enrollment of the 122 interventional ones that give a count, is one of 13 that started in 2024, is one of 28 in phase 2, and was the 133rd registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

10 of the 145 studies in Respiratory Syncytial Virus Infections with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies in Respiratory Syncytial Virus Infections with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical study was to learn more about the study drug, obeldesivir (ODV; GS-5245), and how safe and effective it was in treating nonhospitalized adults with acute respiratory syncytial virus (RSV) infection. The researchers wanted to see if obeldesivir can help participants' symptoms get better faster.

The primary objectives of this study were to evaluate the efficacy of ODV in reducing the duration of symptoms and to evaluate the safety and tolerability of ODV in nonhospitalized adult participants with acute RSV infection.

03

Conditions studied

  • RSV Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Exhibits at least 1 of the following risk factors for severe RSV disease:

    1. Age ≥ 60 years
    2. Moderate or severe (COPD) with a history of exacerbation during the preceding 12 months.
    3. Asthma with a history of ≥ 1 exacerbation during the proceeding 12 months
    4. One or more of the following chronic lung diseases:

      • i) Bronchiectasis
      • ii) Interstitial lung disease (eg, idiopathic pulmonary fibrosis)
      • iii) Pulmonary hypertension
    5. Chronic cardiovascular disease exclusive of hypertension
  • RSV infection confirmed ≤ 3 days before randomization
  • New onset or increased from baseline of ≥ 2 of the following signs and or/symptoms, and at least 1 sign/symptom of moderate severity at screening, and onset ≤ 3 days before randomization.

    • a) Nasal congestion.
    • b) Sore throat.
    • c) Cough.
    • d) Wheezing.
    • e) Shortness of breath (ie, dyspnea).
    • f) Expectoration (ie, sputum production).
  • RSV vaccine status:

    • Individuals whose only risk factor is age ≥ 60 years must not have received any doses of a vaccine for RSV.

Key Exclusion Criteria:

  • Currently requiring or expected to require hospitalization within 48 hours after randomization.
  • Documented previous infection and/or hospitalization for RSV during the current respiratory virus season.
  • Documented to be positive for influenza A or B virus, and/or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ≤ 7 days prior to randomization.
  • Concurrent infections requiring treatment with any systemic antimicrobial therapy ≤ 7 days prior to randomization.
  • Individuals with a history of cystic fibrosis.
  • Undergoing dialysis, known history of moderate or severe renal impairment within the preceding 6 months prior to randomization.
  • Pregnant at screening.
  • Received any approved or authorized, direct-acting antiviral drug or monoclonal antibody against RSV \< 28 days or \< 5 half-lives, whichever is longer, before randomization.
  • Received an product \< 28 days or \< 5 half-lives, whichever is longer, before randomization.
  • ≥ 5 x within 6 months prior to randomization, unless confirmed as resolved at screening.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Obeldesivir

    Participants will receive ODV 700 mg twice on Day 1, followed by ODV 350 mg twice daily on Days 2 to 5.

    Drug: Obeldesivir

  • Experimental
    Placebo

    Participants will receive placebo-to-match (PTM) ODV twice daily for 5 days.

    Drug: Obeldesivir Placebo

Interventions

  • Tablet administered orally

    Also known as: GS-5245

  • DrugObeldesivir Placebo

    Tablet administered orally

06

What researchers measure

Primary outcomes

  1. Time to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms as Measured by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Through Day 15

    RiiQ symptom scale is 13-item questionnaire (6 symptoms related to upper \& lower respiratory tract \& 7 systemic symptoms).Targeted RSV symptoms are 6 respiratory symptoms: nasal congestion, sore throat, cough, expectoration, shortness of breath \& wheezing.Each symptom is rated on scale of None, Mild, Moderate \& Severe.Alleviation of targeted RSV symptoms was defined as for 2 consecutive assessments: non-preexisting symptoms scored was None or Mild; pre-existing symptoms that were present but not worse at baseline scored same or below;\& pre-existing symptoms that were worse at baseline improved at least one scale grade level. Time to alleviation of targeted RSV symptoms by Day 15 for participants with symptom alleviation was calculated as symptom alleviation date/time minus first dose date/time.For participants who completed or discontinued study by Day 15 without symptom alleviation (censored),time was calculated as last date/time on which RiiQ was assessed minus first dose date/time.

    Time frame: Up to Day 15

  2. Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not the AE is considered related to the study drug. TEAEs were defined as any AE that began on or after the date of first dose of study drug up to the date of last dose of study drug plus 30 days and that led to study drug discontinuation. Percentages are rounded off.

    Time frame: Up to 5 days plus 30 days

  3. Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point up to the date of the last dose of study drug plus 30 days. The Division of AIDS (DAIDS) Toxicity Grading Scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that did not meet the criteria for an abnormality of at least Grade 1. Grade 1: mild, Grade 2: moderate, Grade 3: severe, and Grade 4: potentially life-threatening. Percentage are rounded off.

    Time frame: Up to 5 days plus 30 days

  4. Percentage of Participants Who Experienced Serious Adverse Events

    A serious adverse event (SAEs) is defined as an event that, at any dose, results in death, a life-threatening situation, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or a medically important event or reaction. Percentage was rounded off.

    Time frame: Up to 5 days plus 30 days

  5. Percentage of Participants Who Experienced Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation

    TEAEs were defined as any AE that began on or after the date of first dose of study drug up to the date of last dose of study drug plus 30 days and that led to study drug discontinuation. Percentages are rounded off.

    Time frame: Up to 5 days plus 30 days

Secondary outcomes

  1. Time to Sustained Alleviation of Targeted RSV Symptoms as Measured by RiiQ Through Day 15

    RiiQ and targeted RSV symptoms are defined in Outcome Measure #1. Each symptom is rated on scale of None, Mild, Moderate, \& Severe. Sustained alleviation of targeted RSV symptoms was defined similarly to alleviation of targeted RSV symptoms but for 3 consecutive assessments. Time to sustained alleviation of targeted RSV symptoms by Day 15 for participants with sustained symptom alleviation was calculated as symptom alleviation date/time minus first dose date/time. For participants who completed or discontinued study by Day 15 without sustained symptom alleviation (censored), time was calculated as last date/time on which RiiQ was assessed minus first dose date/time.

    Time frame: Up to Day 15

  2. Time to RSV-Related Lower Respiratory Tract Infection (LRTI) Through Day 29

    RiiQ is defined in Outcome Measure #1. Lower Respiratory Tract (LRT) symptoms included cough, expectoration, shortness of breath, and wheezing. Based on RiiQ, RSV-related LRTI was defined as \>=2 of the following symptoms, 1 of which must be reported as at least 'moderate' severity: new or increased cough, new or increased wheezing, new or increased shortness of breath, new or increased expectoration and participant has not met alleviation endpoints. The time to RSV-related LRTI by Day 29 for participants with RSV-related LRTI, was calculated as date/time of meeting LRTI definition minus first dose date/time. For participants who completed Day 29 of the study or discontinued from the study before Day 29 without RSV-related LRTI (censored), time was calculated as last date/time on which RiiQ was assessed minus the first dose date/time.

    Time frame: Up to Day 29

  3. Time to RSV-Related Hospitalization or All-Cause Death Through Day 29

    RSV-related hospitalization is defined as ≥ 24 hours of acute care for a reason related to RSV, in a hospital or similar acute care facility, including emergency rooms or temporary facilities instituted to address medical needs of those with RSV. RSV relatedness was determined by investigator. KM estimates were used in analysis.

    Time frame: Up to Day 29

  4. Time to RSV-Related Medically Attended Visit or All-Cause Death Through Day 29

    Medically attended visits (MAV) are defined as any interactions with health care professionals other than study staff or designees, including hospitalization; in-person emergency, urgent, or primary care visits; or any other in-person visit attended by the participant and a health care professional. RSV relatedness was determined by the investigator. KM estimates were used in analysis.

    Time frame: Up to Day 29

  5. RSV Viral Load At Baseline

    The RSV viral load results were obtained from UTM (universal transport medium) nasal swab samples collected at Baseline.

    Time frame: Baseline

  6. Change From Baseline in RSV Viral Load Through Day 3

    The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 3.

    Time frame: Baseline, Day 3

  7. Change From Baseline in RSV Viral Load Through Day 5

    The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 5.

    Time frame: Baseline, Day 5

  8. Change From Baseline in RSV Viral Load Through Day 7

    The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 7.

    Time frame: Baseline, Day 7

  9. Change From Baseline in RSV Viral Load Through Day 10

    The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 10.

    Time frame: Baseline, Day 10

  10. Change From Baseline in RSV Viral Load Through Day 15

    The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 15.

    Time frame: Baseline, Day 15

  11. Pharmacokinetic (PK) Parameter: AUCtau of GS-441524, Metabolite of Obeldesivir

    AUCtau is defined as area under the plasma concentration-time curve during a dosing interval.

    Time frame: Day 5: Pre-dose and at multiple timepoints (up to 12 hours) post-dose

  12. PK Parameter: Ctrough of GS-441524, Metabolite of Obeldesivir

    Ctrough is defined as the concentration at the end of the dosing interval.

    Time frame: Day 5 (predose)

  13. PK Parameter: Cmax of GS-441524, Metabolite of Obeldesivir

    Cmax is defined as the maximum observed concentration of drug in plasma.

    Time frame: Day 1 (At multiple timepoints [up to 4 hours] post-dose); Day 5 (Pre-dose and at multiple timepoints [up to 4 hours] post-dose)

07

Results

Posted Jun 30, 2026

Participant flow

Participants were enrolled at study sites in the United States.

Participant flow — Overall Study
MilestoneObeldesivirPlacebo
Started7575
Completed7472
Not completed13
Withdrew: Randomized but never treated11
Withdrew: Withdrew consent02

Outcome measures

PrimaryTime to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms as Measured by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Through Day 15

RiiQ symptom scale is 13-item questionnaire (6 symptoms related to upper \& lower respiratory tract \& 7 systemic symptoms).Targeted RSV symptoms are 6 respiratory symptoms: nasal congestion, sore throat, cough, expectoration, shortness of breath \& wheezing.Each symptom is rated on scale of None, Mild, Moderate \& Severe.Alleviation of targeted RSV symptoms was defined as for 2 consecutive assessments: non-preexisting symptoms scored was None or Mild; pre-existing symptoms that were present but not worse at baseline scored same or below;\& pre-existing symptoms that were worse at baseline improved at least one scale grade level. Time to alleviation of targeted RSV symptoms by Day 15 for participants with symptom alleviation was calculated as symptom alleviation date/time minus first dose date/time.For participants who completed or discontinued study by Day 15 without symptom alleviation (censored),time was calculated as last date/time on which RiiQ was assessed minus first dose date/time.

Time frame:
Up to Day 15
Reported as:
Median · days
Time to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms as Measured by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Through Day 15
daysObeldesivirPlacebo
Time to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms as Measured by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Through Day 153.2 (2.9 to 4.0)3.9 (2.7 to 4.9)
Statistical analysis
  • Obeldesivir vs Placebo · Stratified Log-Rank Test · p = 0.2005 (The two-sided p-value was based on stratified log-rank test using vaccination status (Ever/Never) as the strata.) · Difference in median time: -0.7Difference in median time to alleviation of targeted RSV symptoms through Day 15 was calculated between ODV and placebo.
PrimaryPercentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not the AE is considered related to the study drug. TEAEs were defined as any AE that began on or after the date of first dose of study drug up to the date of last dose of study drug plus 30 days and that led to study drug discontinuation. Percentages are rounded off.

Time frame:
Up to 5 days plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
percentage of participantsObeldesivirPlacebo
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)13.516.2
PrimaryPercentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities

Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point up to the date of the last dose of study drug plus 30 days. The Division of AIDS (DAIDS) Toxicity Grading Scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that did not meet the criteria for an abnormality of at least Grade 1. Grade 1: mild, Grade 2: moderate, Grade 3: severe, and Grade 4: potentially life-threatening. Percentage are rounded off.

Time frame:
Up to 5 days plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities
percentage of participantsObeldesivirPlacebo
Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities59.557.5
PrimaryPercentage of Participants Who Experienced Serious Adverse Events

A serious adverse event (SAEs) is defined as an event that, at any dose, results in death, a life-threatening situation, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or a medically important event or reaction. Percentage was rounded off.

Time frame:
Up to 5 days plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Serious Adverse Events
percentage of participantsObeldesivirPlacebo
Percentage of Participants Who Experienced Serious Adverse Events01.4
PrimaryPercentage of Participants Who Experienced Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation

TEAEs were defined as any AE that began on or after the date of first dose of study drug up to the date of last dose of study drug plus 30 days and that led to study drug discontinuation. Percentages are rounded off.

Time frame:
Up to 5 days plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation
percentage of participantsObeldesivirPlacebo
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation01.4
SecondaryTime to Sustained Alleviation of Targeted RSV Symptoms as Measured by RiiQ Through Day 15

RiiQ and targeted RSV symptoms are defined in Outcome Measure #1. Each symptom is rated on scale of None, Mild, Moderate, \& Severe. Sustained alleviation of targeted RSV symptoms was defined similarly to alleviation of targeted RSV symptoms but for 3 consecutive assessments. Time to sustained alleviation of targeted RSV symptoms by Day 15 for participants with sustained symptom alleviation was calculated as symptom alleviation date/time minus first dose date/time. For participants who completed or discontinued study by Day 15 without sustained symptom alleviation (censored), time was calculated as last date/time on which RiiQ was assessed minus first dose date/time.

Time frame:
Up to Day 15
Reported as:
Median · days
Time to Sustained Alleviation of Targeted RSV Symptoms as Measured by RiiQ Through Day 15
daysObeldesivirPlacebo
Time to Sustained Alleviation of Targeted RSV Symptoms as Measured by RiiQ Through Day 153.7 (2.9 to 5.0)4.0 (3.0 to 6.0)
Statistical analysis
  • Obeldesivir vs Placebo · Stratified Log-Rank Test · p = 0.2772 (The two-sided p-value was based on stratified log-rank test using vaccination status (Ever/Never) as the strata, if applicable.) · Difference in median time: -0.3Difference in median time to sustained alleviation of targeted RSV symptoms through Day 15 was calculated between ODV and placebo.
SecondaryTime to RSV-Related Lower Respiratory Tract Infection (LRTI) Through Day 29

RiiQ is defined in Outcome Measure #1. Lower Respiratory Tract (LRT) symptoms included cough, expectoration, shortness of breath, and wheezing. Based on RiiQ, RSV-related LRTI was defined as \>=2 of the following symptoms, 1 of which must be reported as at least 'moderate' severity: new or increased cough, new or increased wheezing, new or increased shortness of breath, new or increased expectoration and participant has not met alleviation endpoints. The time to RSV-related LRTI by Day 29 for participants with RSV-related LRTI, was calculated as date/time of meeting LRTI definition minus first dose date/time. For participants who completed Day 29 of the study or discontinued from the study before Day 29 without RSV-related LRTI (censored), time was calculated as last date/time on which RiiQ was assessed minus the first dose date/time.

Time frame:
Up to Day 29
Reported as:
Median · days
Time to RSV-Related Lower Respiratory Tract Infection (LRTI) Through Day 29
daysObeldesivirPlacebo
Time to RSV-Related Lower Respiratory Tract Infection (LRTI) Through Day 29NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Obeldesivir vs Placebo · Unstratified Log-Rank Test · p = 0.8400 · Hazard ratio (hr): 1.110 · 95% CI 0.402 to 3.061Hazard ratio and two-sided 95% CI were estimated using an unstratified Cox proportional hazards regression model.
SecondaryTime to RSV-Related Hospitalization or All-Cause Death Through Day 29

RSV-related hospitalization is defined as ≥ 24 hours of acute care for a reason related to RSV, in a hospital or similar acute care facility, including emergency rooms or temporary facilities instituted to address medical needs of those with RSV. RSV relatedness was determined by investigator. KM estimates were used in analysis.

Time frame:
Up to Day 29
Reported as:
Median · days
Time to RSV-Related Hospitalization or All-Cause Death Through Day 29
daysObeldesivirPlacebo
Time to RSV-Related Hospitalization or All-Cause Death Through Day 29NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Obeldesivir vs Placebo · Unstratified Log-Rank Test · p = 0.3137
SecondaryTime to RSV-Related Medically Attended Visit or All-Cause Death Through Day 29

Medically attended visits (MAV) are defined as any interactions with health care professionals other than study staff or designees, including hospitalization; in-person emergency, urgent, or primary care visits; or any other in-person visit attended by the participant and a health care professional. RSV relatedness was determined by the investigator. KM estimates were used in analysis.

Time frame:
Up to Day 29
Reported as:
Median · days
Time to RSV-Related Medically Attended Visit or All-Cause Death Through Day 29
daysObeldesivirPlacebo
Time to RSV-Related Medically Attended Visit or All-Cause Death Through Day 29NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Obeldesivir vs Placebo · Unstratified Log-Rank Test · p = 0.9878 · Hazard ratio (hr): 0.985 · 95% CI 0.139 to 6.991Hazard ratio and two-sided 95% CI were estimated using an unstratified Cox proportional hazards regression model.
SecondaryRSV Viral Load At Baseline

The RSV viral load results were obtained from UTM (universal transport medium) nasal swab samples collected at Baseline.

Time frame:
Baseline
Reported as:
Mean · log10 copies/mL
RSV Viral Load At Baseline
log10 copies/mLObeldesivirPlacebo
RSV Viral Load At Baseline5.33 ± 1.5535.58 ± 1.762
SecondaryChange From Baseline in RSV Viral Load Through Day 3

The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 3.

Time frame:
Baseline, Day 3
Reported as:
Least squares mean · log10 copies/mL
Change From Baseline in RSV Viral Load Through Day 3
log10 copies/mLObeldesivirPlacebo
Change From Baseline in RSV Viral Load Through Day 3-1.25 ± 0.275-1.34 ± 0.261
Statistical analysis
  • Obeldesivir vs Placebo · Mixed-effects model repeated measures · p = 0.8204 (p-value was from mixed-effects model repeated measures (MMRM) with baseline RSV viral load and randomization strata as covariates.) · Least squares (ls) mean difference: 0.08LS mean (standard error \[SE\]) was from MMRM with baseline RSV viral load and randomization strata as covariates.
SecondaryChange From Baseline in RSV Viral Load Through Day 5

The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 5.

Time frame:
Baseline, Day 5
Reported as:
Least squares mean · log10 copies/mL
Change From Baseline in RSV Viral Load Through Day 5
log10 copies/mLObeldesivirPlacebo
Change From Baseline in RSV Viral Load Through Day 5-2.41 ± 0.244-1.64 ± 0.238
Statistical analysis
  • Obeldesivir vs Placebo · MMRM · p = 0.0199 (p-value was from MMRM with baseline RSV viral load and randomization strata as covariates.) · Ls mean difference: -0.78LS mean (SE) was from MMRM with baseline RSV viral load and randomization strata as covariates.
SecondaryChange From Baseline in RSV Viral Load Through Day 7

The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 7.

Time frame:
Baseline, Day 7
Reported as:
Least squares mean · log10 copies/mL
Change From Baseline in RSV Viral Load Through Day 7
log10 copies/mLObeldesivirPlacebo
Change From Baseline in RSV Viral Load Through Day 7-2.80 ± 0.185-2.69 ± 0.186
Statistical analysis
  • Obeldesivir vs Placebo · MMRM · p = 0.6652 (p-value was from MMRM with baseline RSV viral load and randomization strata as covariates.) · Ls mean difference: -0.10LS mean (SE) was from MMRM with baseline RSV viral load and randomization strata as covariates.
SecondaryChange From Baseline in RSV Viral Load Through Day 10

The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 10.

Time frame:
Baseline, Day 10
Reported as:
Least squares mean · log10 copies/mL
Change From Baseline in RSV Viral Load Through Day 10
log10 copies/mLObeldesivirPlacebo
Change From Baseline in RSV Viral Load Through Day 10-3.13 ± 0.156-2.77 ± 0.162
Statistical analysis
  • Obeldesivir vs Placebo · MMRM · p = 0.0734 (p-value was from MMRM with baseline RSV viral load and randomization strata as covariates.) · Ls mean difference: -0.36LS mean (SE) was from MMRM with baseline RSV viral load and randomization strata as covariates.
SecondaryChange From Baseline in RSV Viral Load Through Day 15

The RSV viral load results were obtained from UTM nasal swab samples collected at Baseline and Day 15.

Time frame:
Baseline, Day 15
Reported as:
Least squares mean · log10 copies/mL
Change From Baseline in RSV Viral Load Through Day 15
log10 copies/mLObeldesivirPlacebo
Change From Baseline in RSV Viral Load Through Day 15-3.15 ± 0.118-3.21 ± 0.121
Statistical analysis
  • Obeldesivir vs Placebo · MMRM · p = 0.6703 (p-value was from MMRM with baseline RSV viral load and randomization strata as covariates.) · Ls mean difference: 0.06LS mean (SE) was from MMRM with baseline RSV viral load and randomization strata as covariates.
SecondaryPharmacokinetic (PK) Parameter: AUCtau of GS-441524, Metabolite of Obeldesivir

AUCtau is defined as area under the plasma concentration-time curve during a dosing interval.

Time frame:
Day 5: Pre-dose and at multiple timepoints (up to 12 hours) post-dose
Reported as:
Mean · h*ng/mL
Pharmacokinetic (PK) Parameter: AUCtau of GS-441524, Metabolite of Obeldesivir
h*ng/mLObeldesivir
Pharmacokinetic (PK) Parameter: AUCtau of GS-441524, Metabolite of Obeldesivir23300 ± 7860
SecondaryPK Parameter: Ctrough of GS-441524, Metabolite of Obeldesivir

Ctrough is defined as the concentration at the end of the dosing interval.

Time frame:
Day 5 (predose)
Reported as:
Mean · ng/mL
PK Parameter: Ctrough of GS-441524, Metabolite of Obeldesivir
ng/mLObeldesivir
PK Parameter: Ctrough of GS-441524, Metabolite of Obeldesivir865 ± 475
SecondaryPK Parameter: Cmax of GS-441524, Metabolite of Obeldesivir

Cmax is defined as the maximum observed concentration of drug in plasma.

Time frame:
Day 1 (At multiple timepoints [up to 4 hours] post-dose); Day 5 (Pre-dose and at multiple timepoints [up to 4 hours] post-dose)
Reported as:
Mean · ng/mL
PK Parameter: Cmax of GS-441524, Metabolite of Obeldesivir
ng/mLObeldesivir
Day 15560 ± 2500
Day 53740 ± 1890

Adverse events

Collected over All-Cause Mortality: Up to Day 121; Adverse Events: Up to 5 days plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Obeldesivir0/75 (0%)0/74 (0%)0/74 (0%)
Placebo0/75 (0%)1/74 (1.4%)0/74 (0%)
Most frequent serious events
Most frequent serious events
EventObeldesivirPlacebo
PneumoniaInfections and infestations0/741/74

Baseline characteristics

The Safety Analysis Set included all randomized participants who took at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)ObeldesivirPlaceboTotal
<=18 years101
Between 18 and 65 years5248100
>=65 years212647
Age, Continuous
Age, Continuous(years)ObeldesivirPlaceboTotal
Mean54 ± 16.955 ± 16.454 ± 16.6
Sex: Female, Male
Sex: Female, Male(Participants)ObeldesivirPlaceboTotal
Female424082
Male323466
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ObeldesivirPlaceboTotal
Hispanic or Latino5157108
Not Hispanic or Latino231740
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ObeldesivirPlaceboTotal
American Indian or Alaska Native011
Asian303
Native Hawaiian or Other Pacific Islander000
Black or African American9615
White6267129
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)ObeldesivirPlaceboTotal
United States7474148
Respiratory Syncytial Virus (RSV) Viral Load in Universal Transport Medium (UTM)
Respiratory Syncytial Virus (RSV) Viral Load in Universal Transport Medium (UTM)(log10 copies/mL)ObeldesivirPlaceboTotal
Mean5.03 ± 1.7034.84 ± 2.0294.93 ± 1.879
08

Study locations

121 sites
  • Central Alabama Research
    Birmingham, Alabama 35209, United States
  • Cullman Clinical Trials
    Cullman, Alabama 35055, United States
  • Lakeview Clinical Research, LLC
    Guntersville, Alabama 35976, United States
  • Headlands Research-Scottsdale
    Scottsdale, Arizona 85260, United States
  • Epic Medical Research-Surprise
    Surprise, Arizona 85378, United States
  • Clearview Medical Research, LLC
    Canyon Country, California 91350, United States
  • Kaiser Permanente Fontana Medica Center
    Fontana, California 92335, United States
  • University of California, San Francisco-Fresno
    Fresno, California 93701, United States
  • Downtown L.A. Research Center, Inc.
    Los Angeles, California 90017, United States
  • L.A. Universal Research Center, INC.
    Los Angeles, California 90057, United States
  • Stanford
    Palo Alto, California 94304, United States
  • National Institute of Clinical Research, Inc
    Pomona, California 91768, United States
  • Paradigm Clinical Research
    Redding, California 96001, United States
  • M3 Wake Research San Diego
    San Diego, California 92111, United States
  • FOMAT Medical Research - Central Coast Family Care
    Santa Maria, California 93454, United States
  • Med Partners, Inc.
    Toluca Lake, California 91602, United States
  • Allianz Research Institute- Colorado
    Aurora, Colorado 80014, United States
  • Paradigm Clinical Research Centers, LLC., Wheat Ridge
    Wheat Ridge, Colorado 80033, United States
  • Yale University
    New Haven, Connecticut 06510, United States
  • Georgetown University Medical Center
    Washington D.C., District of Columbia 20007, United States
  • Encore Medical Research of Boynton Beach, LLC
    Boynton Beach, Florida 33436, United States
  • C & A Clinical trials Corp
    Cape Coral, Florida 33990, United States
  • Prestige Clinical Research Center Inc
    Coral Gables, Florida 33134, United States
  • Beautiful Minds Clinical Research Center
    Cutler Bay, Florida 33157, United States
  • UHC Research, LLC
    Doral, Florida 33126, United States
  • Dolphin Medical Research
    Doral, Florida 33172, United States
  • Proactive Clinical Research, LLC
    Fort Lauderdale, Florida 33308, United States
  • Aga Clinical Trials
    Hialeah, Florida 33012, United States
  • Indago Research & Health Center, Inc.
    Hialeah, Florida 33012, United States
  • Research In Miami, Inc.
    Hialeah, Florida 33013, United States
  • Doral Medical Research, LLC
    Hialeah, Florida 33016, United States
  • Sync, LLC
    Hialeah, Florida 33016, United States
  • Evolution Clinical Trials
    Hialeah Gardens, Florida 33016, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32217, United States
  • Health Awareness, LLC
    Jupiter, Florida 33458, United States
  • Multi-Specialty Research Associates, Inc.
    Lake City, Florida 32055, United States
  • Accel Research Sites - St. Pete-Largo Clinical Research Unit
    Largo, Florida 33777, United States
  • Clinical Site Partners LLC dba Flourish Research
    Leesburg, Florida 34748, United States
  • Angels Clinical Research Institute
    Miami, Florida 33122, United States
  • LCC Medical Research Institute
    Miami, Florida 33126, United States
  • CCM Clinical Research Group, LLC.
    Miami, Florida 33133, United States
  • Retreat Medical Research
    Miami, Florida 33135, United States
  • Clinical Trial Services, Corp
    Miami, Florida 33144, United States
  • Continental Clinical Research, LLC
    Miami, Florida 33144, United States
  • Dynamic Medical Research, LLC - Miami
    Miami, Florida 33144, United States
  • Nuren Medical & Research Center
    Miami, Florida 33144, United States
  • Advanced Care and Clinical Trials, LLC
    Miami, Florida 33155, United States
  • Cordova Research Institute
    Miami, Florida 33155, United States
  • Miami Clinical Research
    Miami, Florida 33155, United States
  • Research Institute of South Florida, Inc.
    Miami, Florida 33173, United States
  • P&S Research, LLC.
    Miami, Florida 33175, United States
  • Pro Live Medical Research
    Miami, Florida 33175, United States
  • Entrust Clinical Research
    Miami, Florida 33176, United States
  • Links Clinical Trials LLC
    Miami, Florida 33176, United States
  • Reed Medical Research
    Miami, Florida 33176, United States
  • Nuovida Research Center, Corp
    Miami, Florida 33186, United States
  • Pro-Care Research Center
    Miami Gardens, Florida 33014, United States
  • Essential Clinical Research, Inc
    Miami Lakes, Florida 33014, United States
  • Southern Clinical Research, LLC
    Miami Lakes, Florida 33014, United States
  • Oceanic Research Group
    North Miami Beach, Florida 33169, United States
  • Palm Springs Community Health Center
    Palm Springs, Florida 92262, United States
  • USPA Advance Concept Medical Research Group. LLC
    South Miami, Florida 33143, United States
  • Angels Clinical Research Institute
    Tampa, Florida 33614, United States
  • Precision Research Center Inc
    Tampa, Florida 33614, United States
  • Santos Research Center
    Tampa, Florida 33615, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • Encore Medical Research of Weston
    Weston, Florida 33331, United States
  • Agile Clinical Research Trials, LLC
    Atlanta, Georgia 30328, United States
  • Paradigm Clinical Research
    Boise, Idaho 83709, United States
  • Clinical Research Prime
    Idaho Falls, Idaho 83404, United States
  • Metro Infectious Disease Consultants
    Burr Ridge, Illinois 60527, United States
  • Endeavor Health - Clinical Trials Center
    Skokie, Illinois 60077, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Tranquil Clinical Research
    Webster, Iowa 77598, United States
  • CCT Research- Versailles Family Medicine
    Versailles, Kentucky 40383, United States
  • Centennial Medical Group
    Columbia, Maryland 21045, United States
  • Great Lakes Research Institute
    Southfield, Michigan 48075, United States
  • Javara Inc.
    Mankato, Minnesota 56001, United States
  • University of Minnesota
    Saint Paul, Minnesota 55102, United States
  • Hannibal Regional Healthcare System, Inc
    Hannibal, Missouri 63401, United States
  • Clay-Platte Family Medicine/Avacare
    Kansas City, Missouri 64151, United States
  • Velocity Clinical Research
    Lincoln, Nebraska 68510, United States
  • Velocity Clinical Research
    Lincoln, Nebraska 68516, United States
  • Be Well Clinical Studies
    Lincoln, Nebraska 78681, United States
  • Velocity Clinical Research
    Norfolk, Nebraska 68701, United States
  • Clinical Research of South Nevada
    Las Vegas, Nevada 89121, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Weill Cornell Medicine
    New York, New York 10065, United States
  • Prime Global Research, Inc.
    New York, New York 10456, United States
  • NYC Health and Hospitals-Lincoln
    The Bronx, New York 10451, United States
  • Monroe Biomedical Research
    Monroe, North Carolina 28112, United States
  • Eximia Research-NC, LLC
    Raleigh, North Carolina 27607, United States
  • Wake Research
    Raleigh, North Carolina 27612, United States
  • Trial Management Associates, LLC
    Wilmington, North Carolina 28403, United States
  • The Lidner Research Center at The Christ Hospital
    Cincinnati, Ohio 45219, United States
  • Epic Medical Research- Oklahoma
    Chickasha, Oklahoma 73018, United States
  • Velocity Clinical Research - Anderson
    Anderson, South Carolina 29621, United States
  • Central Texas Clinical Research
    Austin, Texas 78705, United States
  • Inquest Clinical Research
    Baytown, Texas 77521, United States
  • PanAmerican Clinical Research, LLC
    Brownsville, Texas 78520, United States

Showing the first 100 of 121 sites. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in May 2025, 6 months.

Results were first posted in Jun 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2024
First posted
Sep 5, 2024
StartActual
Oct 14, 2024
Primary completionActual
May 8, 2025
CompletionActual
Jun 9, 2025
Results first posted
Jun 30, 2026
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06585150
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Sep 5, 2024
Start date
Oct 14, 2024
Primary completion
May 8, 2025
Completion
Jun 9, 2025
Results posted
Jun 30, 2026
Last update
Jun 30, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obeldesivir

Start the discussion